Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 349534, 8 pages
http://dx.doi.org/10.1155/2015/349534
Research Article

In Vitro Bactericidal Activity of 4- and 5-Chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides against MRSA

1Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1/3, 612 42 Brno, Czech Republic
2Department of Infectious Diseases and Microbiology, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1/3, 612 42 Brno, Czech Republic
3CEITEC VFU, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1/3, 612 42 Brno, Czech Republic
4Institute of Organic Chemistry and Technology, Faculty of Chemical Technology, University of Pardubice, Studentska 573, 532 10 Pardubice, Czech Republic
5Department of Inorganic and Organic Chemistry, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic

Received 12 June 2014; Revised 25 September 2014; Accepted 8 October 2014

Academic Editor: Oguz R. Sipahi

Copyright © 2015 Iveta Zadrazilova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Moellering Jr., J. R. Graybill, J. E. McGowan Jr., and L. Corey, “Antimicrobial resistance prevention initiative—an update: proccedings of an expert panel on resistance,” The American Journal of Medicine, vol. 120, no. 7, pp. S4–S25, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. E. Stryjewski and H. F. Chambers, “Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus,” Clinical Infectious Diseases, vol. 46, supplement 5, pp. S368–S377, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. N. Kaku, K. Yanagihara, Y. Morinaga et al., “Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia,” Journal of Infection and Chemotherapy, vol. 20, no. 6, pp. 350–355, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. European Centre for Disease Prevention and Control, “Proportion of methicillin resistant Staphylococcus aureus (MRSA) isolates in participating countries in 2012,” 2014, http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/map_reports.aspx.
  5. G. Sakoulas, P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering Jr., and G. M. Eliopoulos, “Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia,” Journal of Clinical Microbiology, vol. 42, no. 6, pp. 2398–2402, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. H.-J. Tang, C.-C. Chen, W.-C. Ko, W.-L. Yu, S.-R. Chiang, and Y.-C. Chuang, “In vitro efficacy of antimicrobial agents against high-inoculum or biofilm-embedded meticillin-resistant Staphylococcus aureus with vancomycin minimal inhibitory concentrations equal to 2 μg/mL (VA2-MRSA),” International Journal of Antimicrobial Agents, vol. 38, no. 1, pp. 46–51, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. D. M. Sievert, J. T. Rudrik, J. B. Patel, L. C. McDonald, M. J. Wilkins, and J. C. Hageman, “Vancomycin-resistant Staphylococcus aureus in the United States, 2002–2006,” Clinical Infectious Diseases, vol. 46, no. 5, pp. 668–674, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. M. H. Wilcox, “MRSA new treatments on the horizon: current status,” Injury, vol. 42, no. 5, pp. S42–S44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. P. A. Moise, G. Sakoulas, A. Forrest, and J. J. Schentag, “Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 7, pp. 2582–2586, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. Kratky and J. Vinsova, “Salicylanilide ester prodrugs as potential antimicrobial agents—a review,” Current Pharmaceutical Design, vol. 17, no. 32, pp. 3494–3505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. D. J. Bartram, D. M. Leathwick, M. A. Taylor, T. Geurden, and S. J. Maeder, “The role of combination anthelmintic formulations in the sustainable control of sheep nematodes,” Veterinary Parasitology, vol. 186, no. 3-4, pp. 151–158, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. T.-J. R. Cheng, Y.-T. Wu, S.-T. Yang et al., “High-throughput identification of antibacterials against methicillin-resistant Staphylococcus aureus (MRSA) and the transglycosylase,” Bioorganic and Medicinal Chemistry, vol. 18, no. 24, pp. 8512–8529, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. K. Pauk, I. Zadrazilova, A. Imramovsky et al., “New derivatives of salicylamides: preparation and antimicrobial activity against various bacterial species,” Bioorganic and Medicinal Chemistry, vol. 21, no. 21, pp. 6574–6581, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. Vinšova, J. Kozic, M. Krátky et al., “Salicylanilide diethyl phosphates: synthesis, antimicrobial activity and cytotoxicity,” Bioorganic and Medicinal Chemistry, vol. 22, no. 2, pp. 728–737, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. Y. Liu, P. L. Donner, J. K. Pratt et al., “Identification of halosalicylamide derivatives as a novel class of allosteric inhibitors of HCV NS5B polymerase,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 11, pp. 3173–3177, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. J. Wu, J. T. Jan, C. M. Chen et al., “Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 7, pp. 2693–2696, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. D. J. Hlasta, J. P. Demers, B. D. Foleno et al., “Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: pharmacophore identification based on the screening hit closantel,” Bioorganic and Medicinal Chemistry Letters, vol. 8, no. 14, pp. 1923–1928, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. M. E. Brown, J. N. Fitzner, T. Stevens, W. Chin, C. D. Wright, and J. P. Boyce, “Salicylanilides: selective inhibitors of interleukin-12p40 production,” Bioorganic and Medicinal Chemistry, vol. 16, no. 18, pp. 8760–8764, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. B. C. Chenna, B. A. Shinkre, J. R. King, A. L. Lucius, S. V. L. Narayana, and S. E. Velu, “Identification of novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 1, pp. 380–385, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. G. Triola, S. Wetzel, B. Ellinger et al., “ATP competitive inhibitors of d-alanine-d-alanine ligase based on protein kinase inhibitor scaffolds,” Bioorganic and Medicinal Chemistry, vol. 17, no. 3, pp. 1079–1087, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Kratky, J. Vinsova, E. Novotna et al., “Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopeptidase,” Tuberculosis, vol. 92, no. 5, pp. 434–439, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. A. Imramovsky, J. M. Ferriz, K. Pauk, M. Kratky, and J. Vinsova, “Synthetic route for the preparation of 2-hydroxy-N-[1-(2-hydroxyphenylamino)-1-oxoalkan-2-yl]benzamides,” Journal of Combinatorial Chemistry, vol. 12, no. 4, pp. 414–416, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. Clinical and Laboratory Standards Institute (CLSI), “Performance standards for antimicrobial susceptibility testing ; sixteenth informational supplement,” CLSI document M100-S16, CLSI, Wayne, Pa, USA, 2006.
  24. Clinical and Laboratory Standards Institute (CLSI), “Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement,” CLSI Document M100-S24, CLSI, Wayne, Pa, USA, 2014. View at Google Scholar
  25. European Committee on Antimicrobial Susceptibility Testing, “Breakpoint tables for interpretation of MICs and zone diameters, version 4.0,” 2014, http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_4.0.pdf.
  26. Clinical and Laboratory Standards Institute (CLSI), “Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition,” CLSI document M07-A9 PK, CLSI, Wayne, Pa, USA, 2012.
  27. U. Nübel, J. Dordel, K. Kurt et al., “A timescale for evolution, population expansion, and spatial spread of an emerging clone of methicillin-resistant Staphylococcus aureus,” PLoS Pathogens, vol. 6, no. 4, Article ID e1000855, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. G. Boşgelmez-Tınaz, S. Ulusoy, B. Arıdoğan, and F. Coşkun-Arı, “Evaluation of different methods to detect oxacillin resistance in Staphylococcus aureus and their clinical laboratory utility,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 25, no. 6, pp. 410–412, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. F. Martineau, F. J. Picard, P. H. Roy, M. Ouellette, and M. G. Bergeron, “Species-specific and ubiquitous-DNA-based assays for rapid identification of Staphylococcus aureus,” Journal of Clinical Microbiology, vol. 36, no. 3, pp. 618–623, 1998. View at Google Scholar · View at Scopus
  30. R. Schwalbe, L. Steele-Moore, and A. C. Goodwin, Antimicrobial Susceptibility Testing Protocols, CRC Press, Boca Raton, Fla, USA, 2007.
  31. J. J. Hilliard, R. M. Goldschmidt, L. Licata, E. Z. Baum, and K. Bush, “Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems,” Antimicrobial Agents and Chemotherapy, vol. 43, no. 7, pp. 1693–1699, 1999. View at Google Scholar · View at Scopus
  32. J. O. Cha, Y. K. Park, Y. S. Lee, and G. T. Chung, “In vitro biofilm formation and bactericidal activities of methicillin-resistant Staphylococcus aureus clones prevalent in Korea,” Diagnostic Microbiology and Infectious Disease, vol. 70, no. 1, pp. 112–118, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Imramovsky, S. Stepankova, J. Vanco et al., “Acetylcholinesterase-inhibiting activity of salicylanilide N-alkylcarbamates and their molecular docking,” Molecules, vol. 17, no. 9, pp. 10142–10158, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. H. Lullmann, K. Mohr, and M. Wehling, Pharmacology and Toxicology, Grada, Prague, Czech Republic, 2004 (Czech).
  35. H. Basch and H. H. Gadebusch, “In vitro antimicrobial activity of dimethylsulfoxide,” Applied Microbiology, vol. 16, no. 12, pp. 1953–1954, 1968. View at Google Scholar · View at Scopus
  36. G. Lin, G. A. Pankuch, P. C. Appelbaum, and K. Kosowska-Shick, “Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill,” Diagnostic Microbiology and Infectious Disease, vol. 73, no. 3, pp. 287–289, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. National Committee for Clinical Laboratory Standards (NCCLS), “Methods for determining bactericidal activity of antimicrobial agents; approved guideline,” NCCLS document M26-A, NCCLS, Wayne, Pa, USA, 1999.
  38. I. M. Gould, “MRSA bacteraemia,” International Journal of Antimicrobial Agents, vol. 30, no. 1, pp. 66–70, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. D. Kaye, “FDA lowers vancomycin breakpoints for Staphylococcus aureus,” Clinical Infectious Diseases, vol. 47, no. 3, pp. 3–4, 2008. View at Publisher · View at Google Scholar · View at PubMed
  40. M. J. Rybak, B. M. Lomaestro, and J. C. Rotschafer, “Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists,” Clinical Infectious Diseases, vol. 49, no. 3, pp. 325–327, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus